Understanding patient disease and treatment burden in cytomegalovirus

• Research type

  Research Study

• Full title

  Understanding patient disease and treatment burden and experience in cytomegalovirus: Qualitative interviews with patients with post-transplant cytomegalovirus

• IRAS ID

  302042

• Contact name

  Aileen Marshall

• Contact email

  aileen.marshall@nhs.net

• Sponsor organisation

  Takeda Pharmaceuticals

• Duration of Study in the UK

  0 years, 11 months, 15 days

• Research summary

  In this study, one 60 minute interview will be conducted with adult patients who have suffered from post-transplant cytomegalovirus (CMV), specifically with resistant, refractory, intolerant, and/or recurrent CMV with approximately n=5 patients in the UK to learn about their experience with the burden of the CMV infection and treatment.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  21/SC/0413

• Date of REC Opinion

  3 Dec 2021

• REC opinion

  Favourable Opinion